tirzepatide and triglycerides Zepbound (Tirzepatide) for Chronic Weight Management: Uses, Side Effects, Cost Potential mechanisms by which tirzepatide

Connect with our care team at the Center for Cardiovascular Prevention, Metabolism and Lipids at Georgia Heart Institute at 678-928-5942 to learn more.

Phase 1 data published 2021, Phase 2 data published 2023 (NEJM), the Phase 3 program TRIUMPH is ongoing: TRIUMPH-1 , Phase 3 obesity without T2D (n=2,100), results Q4 2025 TRIUMPH-2 , Phase 3 obesity + T2D (n=1,800), results 2026 TRIUMPH-3 , Phase 3 obesity + CV disease (n=1,900), results 2026 TRIUMPH-4 , Phase 3 obesity + knee osteoarthritis, results 2026 TRIUMPH-OUTCOMES , Phase 3 cardiovascular outcome trial (n=15,000+), results 2027 to 2028 FDA approval is expected at the earliest 2026 to 2027 in the obesity indication, similarly for T2DM

Harris If nausea, bloating, or stomach discomfort becomes persistent and doesnt improve with smaller meals, hydration, or time

GHK-Cu is found in blood plasma and is an FDA-approved ingredient in topical antiaging cosmetics but it is currently banned as an injectable because of safety concerns, such as the risk of immune reactions caused by impurities